JP2015516949A - オステオポンチンとカルシウムおよび／またはストロンチウム含有粒子とを含有するナノ粒子凝集体 - Google Patents

オステオポンチンとカルシウムおよび／またはストロンチウム含有粒子とを含有するナノ粒子凝集体 Download PDF

Info

Publication number
JP2015516949A
JP2015516949A JP2015502339A JP2015502339A JP2015516949A JP 2015516949 A JP2015516949 A JP 2015516949A JP 2015502339 A JP2015502339 A JP 2015502339A JP 2015502339 A JP2015502339 A JP 2015502339A JP 2015516949 A JP2015516949 A JP 2015516949A
Authority
JP
Japan
Prior art keywords
opn
species
biofilm
nanoparticle aggregate
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015502339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015516949A5 (https=
Inventor
ビルケダル，ヘンリク
オルセン，ヤコブ
スコフゴード，ヨナス
シュラファー，セバスティアン
ルイーズ マイア，リッケ
ルイーズ マイア，リッケ
ニュヴァド，ベンテ
スチュアート サザーランド，ダンカン
スチュアート サザーランド，ダンカン
ラングボー ヴェイス，ペータ
ラングボー ヴェイス，ペータ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arla Foods AMBA
Original Assignee
Arla Foods AMBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arla Foods AMBA filed Critical Arla Foods AMBA
Publication of JP2015516949A publication Critical patent/JP2015516949A/ja
Publication of JP2015516949A5 publication Critical patent/JP2015516949A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A61K8/0275—Containing agglomerated particulates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015502339A 2012-03-28 2013-03-27 オステオポンチンとカルシウムおよび／またはストロンチウム含有粒子とを含有するナノ粒子凝集体 Pending JP2015516949A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12161802 2012-03-28
EP12161802.9 2012-03-28
PCT/EP2013/056598 WO2013144247A1 (en) 2012-03-28 2013-03-27 Nanoparticle aggregates containing osteopontin and calcium- and/or strontium-containing particles

Publications (2)

Publication Number Publication Date
JP2015516949A true JP2015516949A (ja) 2015-06-18
JP2015516949A5 JP2015516949A5 (https=) 2016-06-02

Family

ID=48141914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015502339A Pending JP2015516949A (ja) 2012-03-28 2013-03-27 オステオポンチンとカルシウムおよび／またはストロンチウム含有粒子とを含有するナノ粒子凝集体

Country Status (13)

Country Link
US (2) US20150044260A1 (https=)
EP (1) EP2830647A1 (https=)
JP (1) JP2015516949A (https=)
KR (1) KR20150004814A (https=)
CN (1) CN104321073A (https=)
AR (1) AR090569A1 (https=)
AU (1) AU2013241750A1 (https=)
CA (1) CA2868684A1 (https=)
CL (1) CL2014002583A1 (https=)
EA (1) EA201491691A1 (https=)
MX (1) MX2014011594A (https=)
NZ (1) NZ700295A (https=)
WO (1) WO2013144247A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021193398A1 (https=) * 2020-03-27 2021-09-30

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5548121B2 (ja) 2007-05-14 2014-07-16 リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク バイオフィルム中の細菌細胞における生理学的分散応答の誘導
US12109284B2 (en) 2016-11-08 2024-10-08 Dentherapy Ltd Compositions comprising fluoride and calcium and method for preparing them
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US20220183933A1 (en) * 2019-03-22 2022-06-16 The Board Of Regents Of The University Of Oklahoma Surface-modified doped titanium dioxide nanoparticles and uses
CN111366733B (zh) * 2020-03-07 2022-02-08 浙江大学 骨桥蛋白作为靶分子在调节肠道菌群定植中的应用
GB202010987D0 (en) 2020-07-16 2020-09-02 Dentherapy Ltd Oral care compositions and methods
GB202110114D0 (en) 2021-07-14 2021-08-25 Dentherapy Ltd Oral care compositions for use in treaatment
WO2023187028A1 (en) * 2022-03-31 2023-10-05 Nadavia Holding Aps Mouthwash composition comprising one or more strontium salt
WO2025008636A1 (en) 2023-07-06 2025-01-09 Dentherapy Ltd Oral care compositions for use in the treatment of dental health conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519239A (ja) * 2000-01-07 2003-06-17 アルラ・フーズ・エイ・エム・ビィ・エイ ミルクからのオステオポンチンの単離のための方法
JP2007512379A (ja) * 2003-12-01 2007-05-17 アルラ・フーズ・エイ・エム・ビィ・エイ 歯科用製剤におけるオステオポンチンの使用
WO2009010071A1 (en) * 2007-07-16 2009-01-22 Aarhus Universitet Osteopontin nanoparticles system for drug delivery
JP2009519254A (ja) * 2005-12-16 2009-05-14 アルラ・フーズ・エイ・エム・ビィ・エイ 創傷治癒過程を改善するウシオステオポンチン製剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ507335A (en) 2000-10-05 2004-10-29 New Zealand Dairy Board Bone health compositions derived from milk comprising an acidic protein fraction but that does not contain CGMP
AU2012222312B2 (en) 2011-03-03 2017-06-08 Arla Foods Amba Method for isolating osteopontin using feeds containing cmp or casein species

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519239A (ja) * 2000-01-07 2003-06-17 アルラ・フーズ・エイ・エム・ビィ・エイ ミルクからのオステオポンチンの単離のための方法
JP2007512379A (ja) * 2003-12-01 2007-05-17 アルラ・フーズ・エイ・エム・ビィ・エイ 歯科用製剤におけるオステオポンチンの使用
JP2009519254A (ja) * 2005-12-16 2009-05-14 アルラ・フーズ・エイ・エム・ビィ・エイ 創傷治癒過程を改善するウシオステオポンチン製剤
WO2009010071A1 (en) * 2007-07-16 2009-01-22 Aarhus Universitet Osteopontin nanoparticles system for drug delivery

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2021193398A1 (https=) * 2020-03-27 2021-09-30

Also Published As

Publication number Publication date
MX2014011594A (es) 2015-07-06
US20170065673A1 (en) 2017-03-09
EA201491691A1 (ru) 2015-04-30
WO2013144247A1 (en) 2013-10-03
CN104321073A (zh) 2015-01-28
CA2868684A1 (en) 2013-10-03
AU2013241750A8 (en) 2014-10-23
US20150044260A1 (en) 2015-02-12
KR20150004814A (ko) 2015-01-13
AU2013241750A1 (en) 2014-10-09
EP2830647A1 (en) 2015-02-04
NZ700295A (en) 2016-07-29
AR090569A1 (es) 2014-11-19
CL2014002583A1 (es) 2015-06-12

Similar Documents

Publication Publication Date Title
JP2015516949A (ja) オステオポンチンとカルシウムおよび／またはストロンチウム含有粒子とを含有するナノ粒子凝集体
He et al. Polyzwitterion manipulates remineralization and antibiofilm functions against dental demineralization
Zhou et al. Remineralization and bacterial inhibition of early enamel caries surfaces by carboxymethyl chitosan lysozyme nanogels loaded with antibacterial drugs
JP7058344B2 (ja) 歯肉健康を促進するための口腔ケア組成物
Bapat et al. The use of nanoparticles as biomaterials in dentistry
JP7058343B2 (ja) 歯肉健康を促進するための口腔ケア組成物
CN101600442B (zh) 口腔护理产物
RU2404738C2 (ru) Стабилизированные комплексы фосфата кальция
JP7058342B2 (ja) 歯肉健康を促進するための口腔ケア組成物
Abdelnabi et al. Effect of different formulations and application methods of coral calcium on its remineralization ability on carious enamel
RU2716134C2 (ru) Стабилизированные композиции на основе олова (II)
JP5973585B2 (ja) ラクトフェリン機能化表面を有する生体模倣ヒドロキシアパタイト粒子を含有するデンタルケア製品
Eshed et al. MgF 2 nanoparticle-coated teeth inhibit Streptococcus mutans biofilm formation on a tooth model
Babayevska et al. Novel nanosystems to enhance biological activity of hydroxyapatite against dental caries
RU2722306C1 (ru) Композиция для регуляции микроэлементного обмена в полости рта
Xu et al. VMT/ACP/Dextran composite nanosheets against dental caries through promoting mineralization of dentin tubules, pH buffering, and antibacterial
US12414904B2 (en) Composition for the remineralization of teeth
Asgartooran et al. Effect of different boron contents within boron-doped hydroxyapatite-chitosan nano-composite on the microhardness of demineralized enamel
Cao et al. Antibacterial and metalloproteinase-inhibited zinc-doped bioactive glass nanoparticles for enhancing dentin adhesion
Madhubala et al. Evaluation of enamel remineralization potential and anticariogenic efficacy of polydopamine coated biogenic amorphous calcium phosphate
Tabari et al. The Effect of Silicone Oil and Nano-hydroxyapatite/Chitosan Powder on Microhardness and Surface Structure of Primary Teeth Enamel After Iron Drop Consumption.
Shakir et al. Innovation of nano-hydrogels loaded with amelogenin peptide and hydroxyapatite nano-particles for remineralisation of artificially induced white spot lesions
Elumalai et al. Remineralizing effect of zinc reinforced synthetic nano-hydroxyapatite on caries-like lesion in human permanent teeth-An in vitro study.
WO2005000251A1 (ja) 再石灰化促進剤、口腔用組成物
Sulistyawati et al. Effectiveness of Nano-hydroxyapatite in Caries Prevention: Literature Review

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170704